AMBER JOHNSON: Open Payments
NPI 1679158075 · MERIDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,851 in 165 payments from 15 companies in 2025. Trend: 2023 $1,608 · 2024 $2,660 · 2025 $3,851
Food & beverage: $3,740Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 29 | $800 |
| ABBVIE INC. | 12 | $462 |
| Janssen Pharmaceuticals, Inc | 18 | $459 |
| Neurocrine BioSciences, Inc. | 22 | $434 |
| Alkermes, Inc. | 19 | $432 |
| E.R. Squibb & Sons, L.L.C. | 23 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $285 |
| Otsuka America Pharmaceutical, Inc. | 11 | $263 |
| Vanda Pharmaceuticals Inc. | 8 | $156 |
| Indivior Inc. | 3 | $85 |
Products named: VRAYLAR, INGREZZA, AUSTEDO XR, UZEDY, COBENFY, CAPLYTA, SPRAVATO, INVEGA SUSTENNA.
Industry payments across CT — which companies pay providers there.
